Prolyl Hydroxylase Enzyme Inhibitors Induced by Hypoxia in Health and Sports Performance
Abstract
Hypoxia-induced prolyl hydroxylase enzyme inhibitors (HIF-PHI) is a therapeutic agent under a new class of drugs that stimulates the body's response to hypoxia without altering the partial pressure of tissues, and induces the responsible genes by the hematopoietic process. These erythropoiesis-stimulating agents can influence human health, enabling new opportunities in the treatment of anemia in patients suffering from chronic kidney disease, however, the same effects also draw the attention of athletes who seek to improve performance. The aim of this study was to describe, through a literature review, the physiological and therapeutic factors of HIF-PHI inhibitors in health, and sports performance. Conducted a survey from PubMed, Lilacs, Scopus and ScienceDirect databases between the years 2011 to 2019. The keywords used were HIF, HIF-PHI, FG-4592, HIF stabilizers and high performance. The results shown by HIF-PHI can positively influence health and sports performance, by stimulating the production of red blood cells, thus favoring a greater supply of oxygen in the body. A differential of this class of drugs is to decrease hepcidin levels that do not affect iron stores in the body. Other effects are seen as a decrease in total cholesterol and LDL, and possible reductions in blood pressure levels. More studies are needed involving this class of drugs in humans, seen that they can be effective in the treatment of some pathologies, thus improving the quality of life of the population.
References
Bernhardy, W.M., Wiesener, M.S., Scigalla, P., Chou J., Schmieder, R.E., e Gunzler, V. (2010). Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J Am Soc Nephrol, v. 21, 2151-2156. https://doi.org/10.1681/ASN.2010010116
Brigandi, RA, Johnson, B., Oei, C., Westerman, M., Olbina, G., Zoysa, J., Roger, SD, Sahay, M., Cross, N., McMahon, L., Guptha, V., Smolyarchuk, EA, Singh, N., Russ, SF, e Kumar, S. (2016). Novel hypoxia inducible factor-prolyl hydroxylase inhibitor (GSK1278863) for anemia in CKD: a 28-day, phase 2A randomized trial. Am J Kidney Dis. 67(6), 861-871. https://doi.org/10.1053/j.ajkd.2015.11.021
Buisson, C., Marchand, A., Bailoux, I., Lahaussois, A., e Martin, L. (2016). Detection by LC-MS/MS of HIF stabilizer FG-4592 used as a new doping agent: investigation on a positive case. Journal of Pharmaceutical and Biomedical, 20(121), 181-187. https://doi.org/10.1016/j.jpba.2016.01.029
Drueke, TB, Locatelli, F., Clyne, N., Eckardt, KU, Macdougall, IC, Tsakiris, D., Burger, HU, e Scherhag, A. (2006). Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med., 355(20), 2071-2084. https://doi.org/10.1056/NEJMoa062276
Forristal, C., e Levesque, J.P. (2014). Targeting the Hypoxia-Sensing Pathway in Clinical Hematology. Stem Cells Transl. Med. 3(2), 135-140. https://doi.org/10.5966/sctm.2013-0134
Forristal, C.E., Winkler, I.G., Nowlan, B., Barbier, V., e Walkinshaw C.E. (2013). Pharmacologic stabilization of HIF-1alpha increases hematopoietic stem cell quiescence in vivo and accelerates blood recovery after severe irradiation. Blood, 121(5), 759-769. https://doi.org/10.1182/blood-2012-02-408419
Franklin Bunn, H. (2013). Erythropoietin. Cold Spring Harb Perspect Med., 3, a011619. https://doi.org/10.1101/cshperspect.a011619
Gupta, N., e Wish, J.B. (2017). Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD. Am J Kidney Dis., 69(6), 815-826. https://doi.org/10.1053/j.ajkd.2016.12.011
Hasse, V.H. (2017). Therapeutic targeting of the HIF oxygen-sensing pathway: Lessons learned from clinical studies. Exp Cell Res., 356(2), 160-165. https://doi.org/10.1016/j.yexcr.2017.05.004
Holdstock, L., Meadowcroft, AM, Maier, R., Johnson, BM, Jones, D., Rastogi, A., Zeig, S., Lepore, JJ, e Cobitz, AR (2016). Four-Week Studies of Oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor GSK1278863 for Treatment of Anemia. J Am Soc Nephrol, 27(4), 1234-1244. https://doi.org/https://doi.org/10.1681/ASN.2014111139
Hong, Y.R., Kim, H.T., Ro, S., Cho, J.M., Lee, S.H., Kim, I.S., e Jung, Y.H. (2014). Discovery of novel 2-[2-(3-hydroxy-pyridin-2-yl)-thiazol-4-yl]-acetamide derivatives as HIF prolyl 4-hydroxylase inhibitors; SAR, synthesis and modeling evaluation, Bioorg. Med & Chem. Lett., 24(14), 3142-3145. https://doi.org/10.1016/j.bmcl.2014.05.003
Hung, S.C., e Tarng, D.C. (2014). ESA and iron therapy in chronic kidney disease: a balance between patient safety and hemoglobina target. Kidney Int., 86, 676–678. https://doi.org/10.1038/ki.2014.179
Jelkmann, W. (2011). Regulation of erythropoietin production. J Physiol., 589(Pt 6), 1251–1258. https://doi.org/10.1113/jphysiol.2010.195057
Lee, DC, Sohn HA, Park, ZY, Oh, S., Kang, YK, Lee, KM, Kang, M., Jang, IJ, Yang, SJ, Hong YK, Noh, H., Kim, JA, Kim, DJ, Bae, KH, Kim, DM, Chung, SJ, Yoo, HS, Yu, DY, Park, KC, e Yeom, YI (2015) A lactate-induced response to hypoxia. Cell., 161(3), 595-609. https://doi.org/10.1016/j.cell.2015.03.011
Locatelli, F., Fishbane, S., Bloco, G.A., e MacDougall, I.C. (2017). Targeting Hypoxia Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients. Am J Nephrol., 45(3), 187-199. https://doi.org/10.1159/000455166
López-Gómes, J.M., Abad, S., e Vega, A. (2016). New expectations in the treatment of anemia in chronic kidney disease. Nefrología, 36(3), 232-6. https://doi.org/10.1016/j.nefroe.2016.07.002
Mitchell, C.J., Shawki, A., Ganz, T., Nemeth, E., e Mackenzie, B. (2014). Functional properties of human ferroportin, a cellular iron exporter reactive also with cobalt and zinc. Am J Physiol Cell Physiol., 306(5), C450–C459. https://doi.org/10.1152/ajpcell.00348.2013
Nagel, S., Talbot, N.P., Mecinović, J., Smith, T.G., Buchan A.M., e Schofield, C.J. (2010). Therapeutic Manipulation of the HIF Hydroxylases. Antioxid. Redox Signal, 12(4), 481-501. https://doi.org/10.1152/ajpcell.00348.2013
Pergola, P.E., Spinowitz, B.S., Hartman, C.S., Maroni, B.J., e Hasse, V.H. (2016). Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease. Kidney Int., 90, 1115-1122. https://doi.org/10.1016/j.kint.2016.07.019
Provenzano, R., Besarab, A., Sun, C.H., Diamond, S.A., Durham, J.H., e Cangiano, J.L. (2016). Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD. Clin J Am Soc Nephrol., 11, 982-991. https://doi.org/10.2215/CJN.06890615
Van Der Weerd, NC, Grooteman, MPC, Bots, ML, Van Den Dorpel, MA, Den Hoedt, CH, Mazairac, AHA, Nubé, MJ, Lars Penne, E., Gaillard, CA, Wetzels, JFM, Wiegerinck, ET, Swinkels, DW, Blankestijn, PJ, e Ter Wee, PM (2012). Investigators. Hepcidin-25 in chronic hemodialysis patients is related to residual kidney function and not to treatment with erythropoiesis stimulating agents. PLoS One, 7(7), e39783. https://doi.org/10.1371/journal.pone.0039783
World Anti Doping Agency (2015). The 2015 prohibited list International Standard. http://www.amawada.org
Yousaf, F., e Spinowitz B. (2016). Hypoxia-inducible factor stabilizers: A new avenue for reducing BP while helping hemoglobin? Curr Hypertens Rep, 18(23), 1-14. https://doi.org/10.1007/s11906-016-0629-6
Zhong, H., Zhou, T., Li, H., Zhong, Z. (2018) The role of hypoxia-inducible factor stabilizers in the treatment of anemia in patients with chronic kidney disease. Drug Design, Development and Therapy, 12, 3003-3011. https://doi.org/10.2147/DDDT.S175887
Copyright (c) 2021 Lecturas: Educación Física y Deportes
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
